Related Experiment Video

Updated: Jun 12, 2026

Particle Agglutination Method for Poliovirus Identification
07:06

Particle Agglutination Method for Poliovirus Identification

Published on: April 20, 2011

Fractional doses of inactivated poliovirus vaccine in Oman

Ali Jafer Mohammed1, Salah AlAwaidy, Shyam Bawikar

  • 1Ministry of Health, Oman.

The New England Journal of Medicine
|June 25, 2010
PubMed

Insights

Fractional doses of inactivated poliovirus vaccine (IPV) given intradermally achieved similar seroconversion rates but lower antibody titers compared to full intramuscular doses. This strategy may enhance vaccine affordability in developing countries.

Area of Science:

  • Immunology
  • Vaccinology
  • Public Health

Background:

  • Evaluating strategies to make inactivated poliovirus vaccine (IPV) affordable for developing countries.
  • Clinical trial conducted in Oman to assess fractional IPV doses in infants.

Purpose of the Study:

  • To compare immunogenicity and reactogenicity of fractional IPV doses versus full IPV doses.
  • To assess the feasibility of using fractional IPV doses for cost-effective vaccination programs.

Main Methods:

  • Infants randomly assigned to receive fractional (0.1 ml, intradermal, jet injector) or full (intramuscular) IPV doses at 2, 4, and 6 months.
  • Seroconversion rates and antibody titers measured 30 days post-vaccination.
  • Oral poliovirus vaccine challenge administered at 7 months with stool sample analysis.

Main Results:

  • Similar seroconversion rates observed for fractional vs. full IPV doses (97.3-97.9% vs. 100%).
  • Significantly lower median antibody titers in the fractional-dose group (P<0.001).
  • Higher poliovirus type 1 excretion in the fractional-dose group post-challenge (74.8% vs. 63.1%, P=0.03).

Conclusions:

  • Fractional IPV doses induce comparable seroconversion but lower antibody titers than full doses.
  • Intradermal fractional IPV administration is a potential strategy for increasing vaccine affordability.
  • Further evaluation needed to confirm long-term efficacy and safety in diverse populations.
Abstract

More Related Videos

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA&#45;Specific Systemic and Mucosal Responses06:02

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses

Published on: February 23, 2024

In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D08:15

In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D

Published on: December 9, 2022

Related Concept Videos

Poliomyelitis01:17

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...
Smallpox01:24

Smallpox

Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Chickenpox01:20

Chickenpox

Chickenpox is an acute, highly contagious disease caused by the varicella-zoster virus (VZV), a double-stranded DNA virus belonging to the Herpesviridae family. Its transmission occurs primarily through the inhalation of respiratory droplets or direct contact with vesicular fluid from skin lesions. The incubation period typically ranges from 10 to 21 days, during which the virus replicates and disseminates through sequential phases within the host. Although generally self-limiting in children,...
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Vaccinations01:51

Vaccinations

Overview